Azenta Inc Dossier
|
SectorHealth Care IndustryMedical Instruments & Supplies Beta (adjusted)1.25 Intrinsic Value $45.48median of 3 methodsbased on filings through 30 Jun 2026 Market Price $34.89Price as of 30 Sep 2026 UndervaluedIntrinsic value is 30% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $1.5B Enterprise Value $1.3B Shares Outstanding 45.8M diluted Moat Rating None Next Earnings Date20 Nov 2026 Last ex-dividend2 Dec 2021 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Azenta is undergoing a complex multi-year strategic transformation from a semiconductor automation provider to a pure-play life sciences infrastructure company. While the company boasts a debt-free balance sheet with substantial cash reserves, near-term performance is pressured by execution hurdles, project rework costs, and a sluggish recovery in biotech capital spending. The recent guidance downgrade in May 2026 and the extension of its long-range plan to 2029 suggest that patience is required as the company works to stabilize margins and integrate acquisitions like UK Biocentre. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$33.00 Mean target$34.80 High · most bullish analyst$37.00 Street targets sit below today's price; our intrinsic value sits above it. Different horizons, different questions. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $33.00 Persistent underutilization in North American labs and prolonged weakness in genomic sequencing volumes continue to drag down Multiomics margins. Further project rework costs or integration delays with UK Biocentre lead to continued EBITDA margin contraction and negative earnings. Base CaseCentral scenario $34.80 Matches the consensus meanAzenta slowly resolves its remaining automated store remediation issues and stabilizes its gross margins. Organic revenue growth remains flat to slightly positive in the near term, in line with revised FY26 guidance, before recovering to mid-single digits by FY27 as the life sciences market stabilizes. Bull CaseUpside scenario $37.00 Successful implementation of the Azenta Business System (ABS) drives rapid margin expansion. A faster-than-expected recovery in biotech R&D spending accelerates demand for automated cryogenic storage and multiomics services. Strategic deployment of its cash pile into high-margin software or specialized services triggers a positive re-rating. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |